Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating MYK-224 for symptomatic obstructive hypertrophic cardiomyopathy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertrophic Cardiomyopathy

Drugs mentioned

• MYK-224

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Cardiomyopathy, Hypertrophic | Phase 2 | Status: TERMINATED